Merck Sells Its CDMO Business to Lonza
Merck is streamlining its portfolio in the Life Science division and selling its CDMO business to Lonza.
Wolfgang Wienand
Lonza Announces Addition of Commercial Spray-Drying Facility at Bend Site
The investment will reinforce the Bend site as a center of excellence for particle engineering and bioavailability enhancement and create a global manufacturing hub for commercial spray-drying.
Lonza Divests Capsules & Health Ingredients Business for $3 Billion
Lonza signs agreement to divest its Capsules & Health Ingredients (CHI) business to Lone Star Funds, for an enterprise value of $3 billion (CHF 2.3 billion).
Wolfgang Wienand to Join Lonza as New CEO
Lonza has appointed Wolfgang Wienand as its new CEO. He will join the company during the summer of 2024 and succeed Albert M. Baehny, who took on the additional responsibility of interim CEO in October 2023 while the search for a permanent CEO took place.
"We Want to Be a Big Fish"
The CDMO (contract development and manufacturing organizations) business has a bright future, of that Siegfried CEO Wolfgang Wienand is certain. The economic advantages alone speak for this compared to in-house production by the pharmaceutical companies themselves. Although Siegfried has already reached sufficient critical size within its industry, he sees the company continuing on its growth path. The goal is to take over an even larger share of the value chain from pharmaceutical companies in the future.
